Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of VBI-2901e in Healthy Adults
NCT05614245Phase 1Withdrawn
- Sponsor
- VBI Vaccines Inc.
- Start
- Mar 2023
- Primary completion
- Jun 2024
- Modality
- Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of VBI-2901 in coronavirus disease 2019 (COVID-19), severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) (6 arms), sponsored by VBI Vaccines Inc. Primary endpoints: Solicited Local Adverse Events, Solicited Systemic Adverse Events and 4 more. Planned start Mar 2023; status: withdrawn.
02
Drugs
VBI-2901
03
Conditions
coronavirus disease 2019 (COVID-19)severe acute respiratory syndrome (SARS)Middle East respiratory syndrome (MERS)
Beyond the preview
Go deeper on NCT05614245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05614245.